Repository logo
 

Fumarate hydratase in cancer: A multifaceted tumour suppressor.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

Schmidt, Christina 
Sciacovelli, Marco 

Abstract

Cancer is now considered a multifactorial disorder with different aetiologies and outcomes. Yet, all cancers share some common molecular features. Among these, the reprogramming of cellular metabolism has emerged as a key player in tumour initiation and progression. The finding that metabolic enzymes such as fumarate hydratase (FH), succinate dehydrogenase (SDH) and isocitrate dehydrogenase (IDH), when mutated, cause cancer suggested that metabolic dysregulation is not only a consequence of oncogenic transformation but that it can act as cancer driver. However, the mechanisms underpinning the link between metabolic dysregulation and cancer remain only partially understood. In this review we discuss the role of FH loss in tumorigenesis, focusing on the role of fumarate as a key activator of a variety of oncogenic cascades. We also discuss how these alterations are integrated and converge towards common biological processes. This review highlights the complexity of the signals elicited by FH loss, describes that fumarate can act as a bona fide oncogenic event, and provides a compelling hypothesis of the stepwise neoplastic progression after FH loss.

Description

Keywords

Cancer, FH, Fumarate, Metabolism, Mitochondria, Fumarate Hydratase, Humans, Mutation, Neoplasms

Journal Title

Semin Cell Dev Biol

Conference Name

Journal ISSN

1084-9521
1096-3634

Volume Title

98

Publisher

Elsevier BV
Sponsorship
Medical Research Council (MC_UU_12022/6)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (722605)
MS and CF are funded by an MRC Core Funding to the MRC Cancer Unit MRC_MC_UU_12022/6, CS is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722605.